A carregar...
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2(+) Metastatic Breast Cancer
Human epidermal growth factor receptor (HER)-2(+) breast cancer is a distinct molecular and clinical entity, the prognosis of which is improved by trastuzumab. However, primary resistance to trastuzumab is observed in >50% of patients with HER-2(+) advanced breast cancer, and the majority of pati...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3233287/ https://ncbi.nlm.nih.gov/pubmed/22020213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0165 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|